```text
Wiki Article
Abciximab (C7E3, 143653-53-6): A Research Reagent Overview
Abciximab, also identified as C7E3 or bearing the CAS number 143653-53-6, functions as a valuable laboratory reagent extensively utilized in platelet research . This Fab fragment selectively targets the glycoprotein IIb/IIIa binding site on thrombocytes , blocking thrombus development. Therefore , it's frequently applied as a method to explore the mechanisms underlying thrombosis and to evaluate the efficacy of antithrombotic therapies. Distribution is typically restricted to academic settings.
```
The Abciximab Compound Research: Utilizing C7E3 Antibody and The 143653-53-6 Substance in Research Investigations
Ongoing studies into abciximab, a antiplatelet agent, frequently utilizes the monoclonal antigen C7E3 and the molecule identified as 143653-53-6. These tools are instrumental for examining abciximab's mode of function, determining its therapeutic effect in various clinical settings, and exploring potential predictors of therapeutic success. Continued study leveraging these specific reagents is likely to generate valuable data for enhancing clinical applications related to cardiovascular illness.
```text
C7E3 abciximab, also known as c7e3fragment, is a GPIIb/IIIa receptor antagonist widely utilized in scientific research. Its primary application lies in platelet aggregation studies, allowing investigators to probe the mechanisms underlying thrombosis and hemostasis. Researchers employ this agent to investigate the role of platelet activation in various disease models, including ischemia-reperfusion injury and inflammation. Beyond basic research, read more abciximab is increasingly used in developing novel antithrombotic therapies and evaluating their efficacy. Furthermore, studies exploring its potential to modulate vascular smooth muscle cell function and reduce intracranial bleeding are ongoing. The availability of c7e3 abciximab facilitates a deeper understanding of platelet-mediated processes and contributes to the advancement of translational medicine. }
```
```text
Investigating Scientific Avenues with this Glycoprotein IIb/IIIa Inhibitor 143653-53-6 via C7E3
Recent studies indicate that the drug (identified as 143653-53-6) offers significant scientific value, particularly when paired with a C7E3 construct. Preliminary findings suggested that this pairing may enhance therapeutic outcomes in various arterial contexts. Further exploration is focused on elucidating the exact process of interaction between this inhibitor and C7E3, encompassing assessment of platelet clumping and vascular protection.
- Current research efforts seek to maximize administration approaches.
- Preclinical models are are being employed to additional assess such hypotheses.
- Human studies are necessary to completely evaluate patient effectiveness.
```
Abciximab (C7E3) for Research: Purity and Details (143653-53-6)
Researchers needing this antibody for laboratory studies should carefully consider purity and precise characteristics. This product is typically supplied as a solid powder and detailed analytical information including verification by LC-MS, binding affinity assays, and endotoxin level testing is available. Confirm the source’s CoA specifies acceptable limits for related substances and meets all QC standards .
High-Purity ReoPro Details & Stock
Acquiring laboratory-grade Abciximab, specifically referencing the antibody C7E3 and identified by the product number 143653-53-6, requires careful consideration of its origin . This antibody is commonly utilized in in vitro studies , particularly those focused on platelet clumping and thrombosis . Available sources offer this reagent in varying volumes, typically ranging from milligram to larger bulk quantities . Kindly advise reviewing the report of analysis to verify quality and appropriateness for your specific purpose. Moreover, ensure the shelf life date before obtaining to maintain optimal efficacy .
- Typical Purity: >95%
- Preservation Conditions: -20°C in suitable conditions
- Application : Platelet Aggregation Suppression Studies